J-P Benoit
Overview
Explore the profile of J-P Benoit including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
217
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Laine A, Gravier J, Henry M, Sancey L, Bejaud J, Pancani E, et al.
J Control Release
. 2014 Jun;
188:1-8.
PMID: 24878182
The determination of the nanocarrier fate in preclinical models is required before any translation from laboratory to clinical trials. Modern fluorescent imaging techniques have gained considerable advances becoming a powerful...
2.
Weyland M, Griveau A, Bejaud J, Benoit J, Coursaget P, Garcion E
Int J Pharm
. 2013 Jun;
454(2):756-64.
PMID: 23769994
Plasmid DNA (pDNA) and small interfering RNAs (siRNAs) are very useful tools for the treatment of cancer. However, pDNA and siRNAs efficacy is restricted by their negative charge and susceptibility...
3.
Weyland M, Manero F, Paillard A, Gree D, Viault G, Jarnet D, et al.
J Control Release
. 2010 Dec;
151(1):74-82.
PMID: 21138749
Taking advantage from the development of SV30, a new analogue of the pro-apoptotic molecule HA14-1, the aim of this study was to functionally evaluate SV30 and to develop safe nanocarriers...
4.
Vinchon-Petit S, Jarnet D, Michalak S, Lewis A, Benoit J, Menei P
Int J Pharm
. 2010 Sep;
402(1-2):184-9.
PMID: 20863875
We evaluated the safety and the efficacy of doxorubicin drug eluting beads "CM-BC1" when used locally in a 9L glioma model. Twenty microlitres of 1mg/ml CM-BC1 (4μg/rat), 10mg/ml CM-BC1 (40μg/rat)...
5.
Roger E, Lagarce F, Garcion E, Benoit J
Eur J Pharm Sci
. 2010 May;
40(5):422-9.
PMID: 20438839
Lipid nanocapsules (LNCs) have been shown to improve paclitaxel (Ptx) bioavailability and transport across an intestinal barrier model. In the present study, the interaction between P-glycoprotein (P-gp) and LNC transport...
6.
Roger E, Lagarce F, Garcion E, Benoit J
J Control Release
. 2009 Aug;
140(2):174-81.
PMID: 19699246
The use of lipid nanocapsules (LNCs) has enabled an improvement of the oral bioavailability of paclitaxel (Ptx). However, mechanisms that support this recent observation are not yet understood. By focusing...
7.
Roger E, Lagarce F, Benoit J
Int J Pharm
. 2009 Jun;
379(2):260-5.
PMID: 19524655
The in vitro gastrointestinal stability of lipid nanocapsules (LNCs) was studied in different media. The size of LNCs was determined in simulated gastric and intestinal media. In updated fasted state...
8.
Morille M, Passirani C, Letrou-Bonneval E, Benoit J, Pitard B
Int J Pharm
. 2009 Jun;
379(2):293-300.
PMID: 19505548
The main objective of gene therapy via a systemic pathway is the development of a stable and non-toxic gene vector that can encapsulate and deliver foreign genetic materials into specific...
9.
Allard E, Huynh N, Vessieres A, Pigeon P, Jaouen G, Benoit J, et al.
Int J Pharm
. 2009 May;
379(2):317-23.
PMID: 19467309
Ferrociphenol (Fc-diOH) is a new molecule belonging to the fast-growing family of organometallic anti-cancer drugs. In a previous study, we showed promising in vivo results obtained after the intratumoural subcutaneous...
10.
Hureaux J, Lagarce F, Gagnadoux F, Clavreul A, Benoit J, Urban T
Int J Pharm
. 2009 May;
379(2):266-9.
PMID: 19467305
In many cell-culture and animal models, the therapeutic effects of the entrapped drugs in lipid nanocapsules (LNCs) were preserved with low toxicity. These results allow foreseeing further preclinical efficiency and...